Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (1919)	4/9/1998 12:38:00 PM
From: sds	Read Replies (1) \| Respond to of 4676

Tony, Formavirsen does not qualify for fast track. Fast track approval is reserved for drugs that treat life-threatening conditions (sometimes they can take a liberal definition there), and it means that the NDA will be reviewed within six months. I would expect something around 12 months for Isis to get approval. It may be a little quicker -- considering the investments Isis has made to speed along the process, I hope it actually works in practice. I'm not surprised by the lack of action today. The stock went from the 12's to the 15's, pretty much because of the Formavirsen information. It will take a major indication (cancer, perhaps Crohn's, RA, etc.) to get this one moving in a meaningful fashion. sds